MicrobiomeDX uses proprietary tools to profile microbiomes, identify host biomarkers, and develop applications to improve cancer outcomes. Through strategic collaborations, we support pre- and clinical evaluations of cancer therapies among cohorts, identify novel diagnostic and therapeutic targets, and contribute to the stratification of patients for therapy selection. The expertise of our founders in oncology, microbiome science, and bioinformatics allows us to pioneer new ways to investigate microbial targets for diagnostic and therapeutic applications.